NCT05785208View on ClinicalTrials.gov

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

PHASE4RecruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

October 31, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Osimertinib

Osimertinib will be administered at a dose of 80 mg daily until disease progression

Trial Locations (11)

10043

SUSPENDED

Ospedale San Luigi, Turin

37129

SUSPENDED

Università degli Studi di Verona, Verona

44129

SUSPENDED

Ospedale Universitario di Parma, Parma

50134

SUSPENDED

Azienda Ospedaliero-Universitaria Careggi, Florence

60020

SUSPENDED

Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona

70124

SUSPENDED

IRCCS Istituto Tumori Giovanni Paolo II, Bari

02100

SUSPENDED

Ospedale San Camillo de Lellis, Rieti

00133

SUSPENDED

Università Policlinico Tor Vergata, Rome

00161

SUSPENDED

Policlinico Umberto I, Rome

00168

RECRUITING

Fondazione Policlinico Gemelli IRCCS, Rome

00184

SUSPENDED

Ospedale San Giovanni-Addolorata, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER